COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

"Fermented Dairy Beverage on Inflammation/Immune Function in Stressful Exercise" (DAD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03099044
Recruitment Status : Completed
First Posted : April 4, 2017
Last Update Posted : January 5, 2018
Information provided by (Responsible Party):
Dairy A Day, Inc.

Brief Summary:
The purpose of this pilot study is to determine the effects of a Single and Double Dose of Fermented Dairy Beverage on immune health and inflammatory status in healthy adults undergoing stressful exercise.

Condition or disease Intervention/treatment Phase
Healthy Subjects Other: Placebo comparator Other: Single Active dose Other: Double Active dose Not Applicable

Detailed Description:

This is a "pilot" study. A total of 45 male subjects will be randomized to receive either Active product (in 2 doses) or placebo. This is a single-blind design (subjects are unaware of product type they are receiving). Randomization is in a 1:1:1 ratio for active test product (in different doses) versus placebo. Products will consume the beverages for a 10-day period. The subjects will be subjected to a defined strenuous exercise protocol on Days 1 and 10 of the study. Blood will be collected on the exercise days (pre- and post-exercise) on Days 1 and 10.

Blood will be analyzed for markers of Immunity and Inflammation, to assess the immuno-supportive and anti-inflammatory properties of the Active product. Product acceptance and tolerability will also be assessed using a VAS scale.

Outcome analysis will be based upon changes over time (from time-point 0) for within group changes as well as between group differences. That is, study will examine differences in end-points from baseline to end-of-study; as well as differences among the three groups.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 45 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Healthy adults; three groups: Placebo, vs Single-Dose and Double Dose of Fermented Dairy Beverage consumed for 10 days. Subjected to stressful exercise at beginning and end of study. Primary outcomes: immune/inflammatory markers. Assess changes in treatment vs placebo.
Masking: Single (Investigator)
Masking Description: Single blind (subjects unaware of treatment identity)
Primary Purpose: Basic Science
Official Title: "Effects of Two Doses of Fermented Dairy Beverage on Inflammation/Immune Function in Healthy Adults Undergoing Stressful Exercise; Compared to a Placebo Beverage"
Actual Study Start Date : February 15, 2017
Actual Primary Completion Date : March 10, 2017
Actual Study Completion Date : July 24, 2017

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Single Active Dose
Subjects are assigned to receive a single Active beverage and a single placebo beverage.
Other: Single Active dose
Subjects consume 1 placebo + 1 Active beverages daily for 10 days. The dose-response controls for volume consumed.

Active Comparator: Double Active Dose
Subjects are assigned to receive 2 doses of Active beverage.
Other: Double Active dose
Subjects consume 2 Active beverages daily for 10 days. The dose-response controls for volume consumed.

Placebo Comparator: Placebo comparator
Subjects are assigned to receive 2 doses of a placebo beverage.
Other: Placebo comparator
Subjects consume 2 placebo beverages daily for 10 days. The dose-response controls for volume consumed.

Primary Outcome Measures :
  1. Changes in Inflammatory and immune biomarkers o IL-6, IL-10, IL-1 beta and TNF-alpha [ Time Frame: Days 1 and 10 of study ]

    IL-6, IL-10, IL-1 beta and TNF-alpha; IgA, IgG, IgM, absolute neutrophil count, absolute lymphocytes, absolute monocytes, and other immune cells.

    As there are multiple variables, statistical Outcome analysis for "within and between group differences" will be based upon changes over time (from time-point 0) for within group changes [in each outcome measure] as well as between group differences. P value for significance is set at P< 0.05 for significance and will include 95% Confidence Intervals where appropriate. As this is a pilot study, no corrective factors for multiple sets of analysis will be employed.

Secondary Outcome Measures :
  1. Ease of consumption (tolerability) of products [ Time Frame: Day 10 of study ]
    Product ease of consumption (tolerability) will be measured by a Visual Analog Scale. On the VAS scale of 1-10, each subject is asked: "How would you rate your tolerability, your acceptance of this product?" This will be done to compare tolerability of the two product types.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • 1. Males, aged 18 to 50 years of age (inclusive) at the time of screening, nonsmokers for at least 10 years at the time of screening and throughout the study.

    2. BMI between 20.0 and 34.9 kg/m2 (inclusive) at the time of screening. 3. Subject is currently exercising less than 150 minutes per week. 4. Subject is in good health and appropriate for exercise as determined by physical examination, medical history, laboratory tests, cardiac monitoring and Physical Activity Readiness Questionnaire (PAR-Q) 5. Subjects must be able to understand the study, agree to the requirements and restrictions, and be willing to give voluntary consent to participate in the study.

    6. Subject states that he is able to jog, run and/or walk on a treadmill for 60 minutes.

Exclusion Criteria:

  • 1. History of any clinically significant cardiovascular (e.g., blocked coronary artery disease, hypertension, hyperlipidemia, Wolff-Parkinson-White syndrome, etc.), respiratory, endocrine (e.g., diabetes I or II, etc.), renal, hepatic, gastrointestinal, hematologic, neurologic, psychiatric, connective tissue (e.g., Marfan syndrome, etc.) disease or disorder, or any uncontrolled medical illness which in the opinion of the Investigator would jeopardize the safety of the subject, interfere with study assessments, or impact the validity of the study results.

    2. Family history of any first degree relative (mother, father, sibling, child) with myocardial infarction before age 50 or any first degree relative with sudden, unexplained cardiac death.

    3. Subject with a positive result for or history of positive test result(s) for human immunodeficiency virus (HIV) antibody, Hepatitis B surface antigen or Hepatitis C antibody.

    4. Subject has a history of cancer (except localized skin cancer without metastases) within five years prior to screening.

    5. Subject has any current orthopedic problem(s) or clinically significant history of musculoskeletal injury(ies) of the legs that the PI feels may interfere with the study exercise.

    6. Subjects who are not deemed as healthy by standard physical, medical history and other means of screen testing (vitals, blood work, etc.) per PI review and discretion.

    7. Subject who is currently taking or has taken probiotics within 30 days prior to the baseline visit.

    8. Subjects who ingests yogurt (regular, Greek or Icelandic), Kefir or any fermented dairy products four or more times per week regularly within the month prior to baseline visit.

    9. Subject who regularly consumes fermented beverages, such as Kombucha. Regular is defined as more than twice per week and for more than two-weeks consistently, within the 3 months prior to baseline visit.

    10. Subject has a known or suspected allergy or hypersensitivity to trial product(s), including lactose intolerance and or dairy allergies or related product(s).

    11. Subject exhibits evidence of hepatic or renal dysfunction as evidenced by ALT or AST being ≥ 2 times the upper limit of normal or serum creatinine value ≥ 2.0 mg/dl or other clinically significant abnormal clinical laboratory value per PI discretion.

    12. Abnormal electrocardiogram (ECG) results thought to be potentially clinically significant according to the Investigator, or QT prolongation, as evidenced by QTcF >450 msec.

    13. Subject has a recent history (within 12 months of Screening) of substance or alcohol abuse.

    14. Subject has taken an investigational product within 30 days of study enrollment (Visit 1).

    15. Subject who is currently taking any concomitant medications, including prescription or over the counter (OTC), herbal or dietary supplements, vitamin and/or mineral supplements, or NSAIDS or any other anti-inflammatory products, from 7 days prior to baseline and throughout the study (other than study products).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03099044

Layout table for location information
United States, Missouri
QPS Bio-Kinetic Clinical Applications, LLC
Springfield, Missouri, United States, 65802
Sponsors and Collaborators
Dairy A Day, Inc.
Layout table for investigator information
Principal Investigator: Mark R Smith, M.D. QPS Bio-Kinetic Clinical Applications, LLC
Layout table for additonal information
Responsible Party: Dairy A Day, Inc. Identifier: NCT03099044    
Other Study ID Numbers: 69716
First Posted: April 4, 2017    Key Record Dates
Last Update Posted: January 5, 2018
Last Verified: January 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: There is no such plan.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Pathologic Processes